404575-32-2

Basic information

• Product Name: 3-(2-BROMO-4-FLUORO-PHENYL)-PROPAN-1-OL
• Synonyms: 3-(2-BROMO-4-FLUORO-PHENYL)-PROPAN-1-OL
• CAS NO: 404575-32-2
• Molecular Formula: C₉H₁₀BrFO
• Molecular Weight: 233.0775032
• Mol File: 404575-32-2.mol

Chemical Properties

• Boiling Point: 295.772°C at 760 mmHg
• Flash Point: 132.678°C
• Appearance: /
• Density: 1.488g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.547
• CAS DataBase Reference: 3-(2-BROMO-4-FLUORO-PHENYL)-PROPAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-BROMO-4-FLUORO-PHENYL)-PROPAN-1-OL(404575-32-2)
• EPA Substance Registry System: 3-(2-BROMO-4-FLUORO-PHENYL)-PROPAN-1-OL(404575-32-2)

Safety Data

• Hazardous Substances Data: 404575-32-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H10BrFO/c10-9-6-8(11)4-3-7(9)2-1-5-12/h3-4,6,12H,1-2,5H2

Upstream product

• 174603-55-5 3-(2-bromo-4-fluoro-phenyl)-propionic acid 
• 59142-68-6 2-bromo-4-fluorobenzaldehyde 

Downstream Products

• 404575-33-3 [3-(2-Bromo-4-fluoro-phenyl)-propoxyl]-dimethyl-(1,1,2-trimethyl-propyl)-silane 

Relevant articles and documents

Highly Diastereoselective Synthesis of Medium-Sized Carbocycle-Fused Piperidines via Sequential Hydride Shift Triggered Double C(sp3)-H Bond Functionalization

Herein we report a diastereoselective synthesis of medium-sized carbocycle-fused piperidines via [1,n (n = 6, 7)]-[1,5]-sequential hydride shift triggered double C(sp3)-H bond functionalization. When cinnamylidene malonates having N,N-dibenzyl propylamine moiety were treated with 5 mol % of Yb(OTf)3, a [1,6]-[1,5]-sequential hydride shift/cyclization process proceeded to afford seven-membered carbocycle-fused piperidines with excellent diastereoselectivities. This sequential system was applicable to the synthesis of eight-membered carbocycle-fused piperidines by an unprecedented [1,7]-[1,5]-sequential hydride shift/cyclization process.

Construction of seven-and eight-membered carbocycles by Lewis acid catalyzed C(sp3)-H bond functionalization

We achieved a concise construction of seven-and eight-membered carbocycles via Lewis acid catalyzed C(sp3)-H bond functionalization. In these reactions, a quite rare [1,6 (or 7)]-hydride shift/cyclization process proceeded smoothly to afford seven-and eight-membered carbocycles with good chemical yields starting from substrates with high conformational freedom.

PROSTAGLANDIN E RECEPTOR ANTAGONISTS

The present invention provides prostaglandin receptor antagonist compounds represented by the general formula I, wherein A, R, R1 and R2 are as defined in the specification.

Prostaglandin EP4 antagonist

Disclosed herein are methods and compositions related to compound 1 or a pharmaceutically acceptable salt, or a prodrug thereof (all of which are referred to hereafter, collectively or individually, as “compound 1”), which is an antagonist of a prostaglandin EP4 receptor, or is a prostaglandin EP4 antagonist. Also disclosed is a method comprising administering a prostaglandin EP4 antagonist to a mammal suffering from, or at risk of developing, a disease or condition selected from the group consisting of cancer, immunological disorders, neurodegenerative disorders, ocular diseases, hepatic diseases, renal diseases, septicemia, fibromyalgia, dermatological disorders, and antipyrexia.

Prostaglandin D2 antagonist

Disclosed herein is compound 1 or a pharmaceutically acceptable salt, or a prodrug thereof. Compound 1 is useful for treating or preventing a variety of diseases or conditions. Results presented herein also demonstrate that Compound 1 is a prostaglandin D2 antagonist, and as such is useful in the treatment or prevention of prostaglandin D2 mediated conditions or diseases. A method comprising administering a prostaglandin D2 antagonist to a mammal suffering from a disease or condition selected from the group consisting of the gastrointestinal tract disorders or diseases, hyperalgesia, allodynia, abdominal cramping, glaucoma, ocular hypertension, and ocular hypotension is also disclosed herein. Pharmaceutical compositions and products comprising compound 1 are also disclosed.

Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists

The present invention provides novel compounds represented by the general formula I. wherein m, n, X, Y, Z, R, R1and R2are as defined in the specification or a pharmaceutically acceptable salt thereof. The novel compounds are PGF2αantagonists, useful in pharmaceutical compositions for treating PGF2α-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.

Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists

The present invention provides novel compounds represented by the general formula I. wherein m is an integer of from 1 to 3; n is 0 or an integer of from 1 to 4; R is selected from the group consisting of CO2H, CO2R6, CH2OH, CH2O R6 ?and CONR3R4; R1and R2are independently selected from the group consisting of H, R6, C1-C6alkenyl, C1-C6alkynyl, C3-C7cycloalkyl, C4-C12alkylcycloalkyl, C6-C10aryl, C7-C12alkyl aryl radicals and heteroatom-substituted derivatives thereof, wherein one or more of the hydrogen or carbon atoms in said radicals is replaced with a halogen, nitrogen or sulfur-containing radical; R3and R4are selected from the group consisting of H and R6; and X is selected from the group consisting of R6, hydroxy, N(R6)2, CON(R6)2, SR6, sulfoxy, sulfone, halogen, COOR6, NO2, CN and OR6, wherein R6is C1-C6alkyl, and pharmaceutically acceptable salts thereof. The novel compounds are PGF2αantagonists, useful in pharmaceutical compositions for treating PGF2α-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.

Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists

The present invention provides novel compounds represented by the general wherein m, n, X, Y, Z, R, R1 and R2 are as defined in the specification or a pharmaceutically acceptable salt thereof. The novel compounds are PGF2α antagonists, useful in pharmaceutical compositions for treating PGF2α-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.

Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists

The present invention provides novel compounds represented by the general formula I. wherein m is an integer of from 1 to 3; n is 0 or an integer of from 1 to 4; R is selected from the group consisting of CO2H, CO2R6, CH2OH, CH2O R6P(O)(OH)2, ?and CONR3R4; R1and R2are independently selected from the group consisting of H, R6, C1-C6alkenyl, C1-C6alkynyl, C3-C7cycloalkyl, C4-C12alkylcycloalkyl, C6-C10aryl, C7-C12alkyl aryl radicals and heteroatom-substituted derivatives thereof, wherein one or more of the hydrogen or carbon atoms in said radicals is replaced with a halogen, nitrogen or sulfur-containing radical; R3and R4are selected from the group consisting of H and R6; and X is selected from the group consisting of H, R6, hydroxy, N(R6)2, CON(R6)2, SR6, sulfoxy, sulfone, halogen, COOR6, NO2, CN and OR6, wherein R6is C1-C6alkyl; Y is O or S; Z is N or CH and pharmaceutically acceptable salts thereof. The novel compounds are PGF2αantagonists, useful in pharmaceutical compositions for treating PGF2α-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.